KRRO-121

About Korro Bio

Korro Bio is a clinical-stage biotechnology company developing RNA editing therapies via its proprietary OPERA® platform, which co-opts the endogenous ADAR enzyme to make precise adenosine-to-inosine edits. The company has built a diversified pipeline of wholly-owned programs, with its lead candidate, KRRO-121, advancing towards the clinic for hyperammonemia. Korro's strategy leverages validated delivery technologies like GalNAc and LNPs to target high-need indications in the liver and CNS, supported by recent capital raises including an $85 million private placement in March 2026.

Therapeutic Areas